An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments
Each year millions of nonhuman animals suffer in biomedical experiments for human health benefits. Clinical ethics demand that nonhuman animals are used in the development of pharmaceuticals and vaccines. Nonhuman animals are also used for fundamental biomedical research. Biomedical research that us...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-07-01
|
Series: | Animals |
Subjects: | |
Online Access: | http://www.mdpi.com/2076-2615/5/3/0376 |
id |
doaj-2d026faeb11545668ea5d1d4b41ca2d8 |
---|---|
record_format |
Article |
spelling |
doaj-2d026faeb11545668ea5d1d4b41ca2d82020-11-24T22:34:25ZengMDPI AGAnimals2076-26152015-07-015362464210.3390/ani5030376ani5030376An Insufferable Business: Ethics, Nonhuman Animals and Biomedical ExperimentsKay Peggs0Oxford Centre for Animal Ethics, School of Social, Historical and Literary Studies, University of Portsmouth, Milldam, Burnaby Road, Portsmouth PO1 3AS, Hampshire, UKEach year millions of nonhuman animals suffer in biomedical experiments for human health benefits. Clinical ethics demand that nonhuman animals are used in the development of pharmaceuticals and vaccines. Nonhuman animals are also used for fundamental biomedical research. Biomedical research that uses nonhuman animals is big business but the financial gains are generally occluded. This paper explores how such research generates profits and gains for those associated with the industry. Research establishments, scientists, laboratories, companies that sell nonhuman animal subjects, that supply equipment for the research, and corporations that market the resulting products are among those that benefit financially. Given the complex articulation of ethical codes, enormous corporate profits that are secured and personal returns that are made, the accepted moral legitimacy of such experiments is compromised. In order to address this, within the confines of the moral orthodoxy, more could to be done to ensure transparency and to extricate the vested financial interests from the human health benefits. But such a determination would not address the fundamental issues that should be at the heart of human actions in respect of the nonhuman animals who are used in experiments. The paper concludes with such an address by calling for an end to the denigration of nonhuman animals as experimental subjects who can be used as commodities for profit-maximisation and as tools in experiments for human health benefits, and the implementation of a more inclusive ethic that is informed by universal concern about the suffering of and compassion for all oppressed beings.http://www.mdpi.com/2076-2615/5/3/0376anthropocentricbiomedicalbusinessethicsexperimentsnonhuman animalsprofits |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kay Peggs |
spellingShingle |
Kay Peggs An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments Animals anthropocentric biomedical business ethics experiments nonhuman animals profits |
author_facet |
Kay Peggs |
author_sort |
Kay Peggs |
title |
An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments |
title_short |
An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments |
title_full |
An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments |
title_fullStr |
An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments |
title_full_unstemmed |
An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments |
title_sort |
insufferable business: ethics, nonhuman animals and biomedical experiments |
publisher |
MDPI AG |
series |
Animals |
issn |
2076-2615 |
publishDate |
2015-07-01 |
description |
Each year millions of nonhuman animals suffer in biomedical experiments for human health benefits. Clinical ethics demand that nonhuman animals are used in the development of pharmaceuticals and vaccines. Nonhuman animals are also used for fundamental biomedical research. Biomedical research that uses nonhuman animals is big business but the financial gains are generally occluded. This paper explores how such research generates profits and gains for those associated with the industry. Research establishments, scientists, laboratories, companies that sell nonhuman animal subjects, that supply equipment for the research, and corporations that market the resulting products are among those that benefit financially. Given the complex articulation of ethical codes, enormous corporate profits that are secured and personal returns that are made, the accepted moral legitimacy of such experiments is compromised. In order to address this, within the confines of the moral orthodoxy, more could to be done to ensure transparency and to extricate the vested financial interests from the human health benefits. But such a determination would not address the fundamental issues that should be at the heart of human actions in respect of the nonhuman animals who are used in experiments. The paper concludes with such an address by calling for an end to the denigration of nonhuman animals as experimental subjects who can be used as commodities for profit-maximisation and as tools in experiments for human health benefits, and the implementation of a more inclusive ethic that is informed by universal concern about the suffering of and compassion for all oppressed beings. |
topic |
anthropocentric biomedical business ethics experiments nonhuman animals profits |
url |
http://www.mdpi.com/2076-2615/5/3/0376 |
work_keys_str_mv |
AT kaypeggs aninsufferablebusinessethicsnonhumananimalsandbiomedicalexperiments AT kaypeggs insufferablebusinessethicsnonhumananimalsandbiomedicalexperiments |
_version_ |
1725727644730785792 |